Published in Br J Cancer on September 23, 2002
Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours. J Clin Pathol (2004) 2.36
Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer (2003) 2.20
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist (2010) 1.22
The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. Breast Cancer Res Treat (2011) 1.06
Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. Int J Radiat Oncol Biol Phys (2008) 0.92
The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep (2013) 0.90
ARTEMIN promotes de novo angiogenesis in ER negative mammary carcinoma through activation of TWIST1-VEGF-A signalling. PLoS One (2012) 0.89
The role of vascular endothelial growth factor a polymorphisms in breast cancer. Int J Mol Sci (2012) 0.87
Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry. Curr Med Chem (2010) 0.83
In vivo "MRI phenotyping" reveals changes in extracellular matrix transport and vascularization that mediate VEGF-driven increase in breast cancer metastasis. PLoS One (2013) 0.79
Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Invest New Drugs (2016) 0.75
VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug. Oncogene (2017) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med (1995) 26.60
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 5.20
Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev (1993) 3.96
Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer (1983) 3.94
Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol (1994) 3.48
Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res (2000) 2.63
Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst (1991) 2.29
Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst (1997) 1.87
Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res (1997) 1.74
Angiogenesis and metastasis. Eur J Cancer (1996) 1.72
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res (2001) 1.71
High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res (2001) 1.70
Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat (1995) 1.67
Angiogenesis and breast cancer metastasis. Lancet (1995) 1.55
Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol (1998) 1.47
Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery (1996) 1.44
Consensus statement: treatment of early-stage breast cancer. National Institutes of Health Consensus Development Panel. J Natl Cancer Inst Monogr (1992) 1.38
Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst (1993) 1.37
Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol (1999) 1.30
Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery (2001) 1.29
Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol (1997) 1.23
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol (1998) 1.19
Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res (1995) 1.18
Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer (1997) 1.16
p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer (2000) 1.14
Breast cancer therapy--the price of success. N Engl J Med (1992) 1.13
Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer (1980) 1.10
Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol (1999) 1.08
Vascular endothelial growth factor expression is increased in renal cell carcinoma. J Urol (1997) 1.07
Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res (1999) 0.99
Prognostic factors in breast cancer. Semin Surg Oncol (1989) 0.97
Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer? Br J Cancer (1999) 0.95
Vascular endothelial growth factor: a key mediator of neoangiogenesis. A review. Eur Rev Med Pharmacol Sci (1998) 0.95
Angiogenesis in malignancies of the female genital tract. Gynecol Oncol (1999) 0.94
EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers (2000) 0.93
The association between vascular endothelial growth factor, microvessel density and clinicopathological features in invasive cervical cancer. Eur J Obstet Gynecol Reprod Biol (2000) 0.89
Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer (1995) 0.88
Prognostic factors for breast cancer: have they met their promise? J Clin Oncol (1992) 0.87
Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology (2001) 0.87
Contribution of vascular endothelial growth factor to the Nottingham prognostic index in node-negative breast cancer. Br J Cancer (2001) 0.86
Vascular endothelial growth factor in ovarian cyst fluid. Cancer (2001) 0.84
Expression of vascular endothelial growth factor gene and its receptor (flt-1) gene in urinary bladder cancer. Tohoku J Exp Med (1998) 0.79
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev (1992) 2.44
Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst (2010) 1.78
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer (2003) 1.74
Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol (2004) 1.67
Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. Br J Cancer (2003) 1.63
c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res (1992) 1.59
Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. Br J Cancer (2001) 1.55
Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst (2000) 1.54
The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem (1995) 1.42
[Palliation in patients with metastatic breast cancer often better with antitumour treatment than with only symptomatic treatment]. Ned Tijdschr Geneeskd (2007) 1.40
Decreased prolactin response to hypoglycaemia in patients with rheumatoid arthritis: correlation with disease activity. Ann Rheum Dis (2004) 1.40
Presence of symptoms and timing of surgery do not affect the prognosis of patients with primary metastatic breast cancer. Eur J Surg Oncol (2011) 1.40
Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene (2002) 1.34
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer (1992) 1.26
Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma. Cancer (2003) 1.23
Development of quality indicators for diagnosis and treatment of patients with non-small cell lung cancer: a first step toward implementing a multidisciplinary, evidence-based guideline. Lung Cancer (2006) 1.22
Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res (1995) 1.19
Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol (1998) 1.19
Methylated genes as new cancer biomarkers. Eur J Cancer (2009) 1.16
Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. Oncogene (2006) 1.15
Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res (1992) 1.14
The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging (2013) 1.14
High incidence of somatostatin receptors in human meningiomas: biochemical characterization. J Clin Endocrinol Metab (1986) 1.13
Differential regulation of breast tumor cell proliferation by stromal fibroblasts of various breast tissue sources. Int J Cancer (1996) 1.13
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat (2011) 1.12
Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol (2009) 1.12
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. Eur J Cancer (2013) 1.12
Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br J Cancer (2001) 1.08
Tamoxifen resistance in breast cancer: elucidating mechanisms. Drugs (2001) 1.08
Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. Oncogene (2003) 1.08
FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer (2004) 1.08
A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost (2012) 1.08
Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res (1987) 1.07
The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat (1994) 1.07
EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer (2003) 1.05
The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer (1997) 1.05
Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene (1995) 1.04
Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids (2000) 1.03
Stromal influences on breast cancer cell growth. Br J Cancer (1992) 1.03
Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br J Cancer (1990) 1.02
Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res (1992) 1.02
Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. clinical outcomes and oncologists' preferences. Eur J Cancer (2003) 1.02
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res (2001) 1.02
Stress and outcome success in IVF: the role of self-reports and endocrine variables. Hum Reprod (2005) 1.01
TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. Genes Chromosomes Cancer (1996) 1.00
Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer (2001) 0.99
Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer (2013) 0.98
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer. Breast Cancer Res Treat (2010) 0.98
The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot study. Eur J Cancer (1993) 0.98
Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer (1996) 0.97
Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer. Br J Cancer (1998) 0.97
Differential expression of estrogen, progesterone, and epidermal growth factor receptors in normal, benign, and malignant human breast tissues using dual staining immunohistochemistry. Am J Pathol (1994) 0.97
Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer (1992) 0.97
Association between RB-1 gene alterations and factors of favourable prognosis in human breast cancer, without effect on survival. Int J Cancer (1995) 0.96
Infrequent CDKN2 (MTS1/p16) gene alterations in human primary breast cancer. Br J Cancer (1995) 0.96
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer. Br J Cancer (2009) 0.95
Fertility in patients with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab (2006) 0.94
Hydroxyapatite assay to measure epidermal growth factor receptor in human primary breast tumors. Ann Clin Biochem (1990) 0.94
Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands. Breast Cancer Res Treat (2011) 0.94
Regulation of the urokinase-type plasminogen activator system by the von Hippel-Lindau tumor suppressor gene. Cancer Res (1999) 0.94
Transsphenoidal pituitary surgery via the endoscopic technique: results in 35 consecutive patients with Cushing's disease. Eur J Endocrinol (2006) 0.94
EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts. Int J Biol Markers (2000) 0.93
Repeated mammographic screening reduces breast cancer mortality along the continuum of age. J Med Screen (2002) 0.93
Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat (2001) 0.93
Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics. Cancer Treat Rev (2013) 0.92
Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay. Br J Cancer (1992) 0.92
Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue. Int J Biol Markers (2001) 0.91
Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane. Clin Exp Metastasis (1997) 0.91
Loss of imprinting of IGF2 and not H19 in breast cancer, adjacent normal tissue and derived fibroblast cultures. FEBS Lett (1998) 0.91
Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors. Crit Rev Oncol Hematol (2009) 0.91
The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol (2000) 0.91
Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat (1998) 0.91
Metabolic profile of the hippocampus of Zucker Diabetic Fatty rats assessed by in vivo 1H magnetic resonance spectroscopy. NMR Biomed (2004) 0.91
Induction of estrogen independence of ZR-75-1 human breast cancer cells by epigenetic alterations. Mol Endocrinol (1994) 0.91
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. Contrast Media Mol Imaging (2014) 0.90
Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS (1999) 0.90
Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psychooncology (2011) 0.90
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer. Eur J Cancer (2013) 0.90
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. Br J Cancer (2002) 0.89
Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review. Eur Radiol (2012) 0.88
Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors. Int J Cancer (1990) 0.88
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration. Oncol Rep (2005) 0.88
Variation in management of early breast cancer in the Netherlands, 2003-2006. Eur J Surg Oncol (2010) 0.88
Prognostic factors and response to therapy in breast cancer. Cancer Surv (1993) 0.88
Serial plasma concentrations of atrial natriuretic peptide, plasma renin activity, aldosterone, and antidiuretic hormone in neonates on extracorporeal membrane oxygenation. ASAIO J (2002) 0.88
Impaired Sertoli cell function in males diagnosed with Noonan syndrome. J Pediatr Endocrinol Metab (2008) 0.88
Sperm integrity pre- and post-chemotherapy in men with testicular germ cell cancer. Hum Reprod (2006) 0.88
Clinical breast cancer, new developments in selection and endocrine treatment of patients. J Steroid Biochem Mol Biol (1992) 0.88
Fetal growth and the function of the adrenal cortex in preterm infants. J Clin Endocrinol Metab (2002) 0.87
Relevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer. Br J Cancer (2010) 0.87
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. Br J Cancer (2012) 0.87
Six methods for direct radioiodination of mouse epidermal growth factor compared: effect of nonequivalence in binding behavior between labeled and unlabeled ligand. Clin Chem (1991) 0.87
An ELISA avoiding interference by heterophilic antibodies in the measurement of components of the plasminogen activation system in blood. J Immunol Methods (2002) 0.86